Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more on the deal and its PFE implications.

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Recently, BioNTech SE announced an $800 million acquisition of Biotheus ... subject to customary regulatory approvals and 3SBio shareholder consent. Upon completion, Pfizer will also make a $100 ...

The acquisition of SSGJ-707 coincides with Pfizer and Summit collaborating on ... stated that no changes are expected when asked how the 3SBio deal would impact its partnership with Summit.

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

Pfizer has signed a worldwide licensing agreement, excluding China, with biopharmaceutical company 3SBio to develop, manufacture and commercialise bispecific antibody targeting programmed cell ...

Pfizer Inc. announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.'s bispecific antibody SSGJ-707.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China rights to a clinical candidate, establishing itself as a challenger to ...